Dr Doroshow (National Cancer Institute, Bethesda, USA), Dr Flaherty (Massachusetts General Hospital, Boston, USA) and Dr Conley (Division of Cancer Treatment & Diagnosis, NCI , USA) present, at a press conference at ASCO 2015, about the trial: NCI-Molecular Analysis for Therapy Choice (NCI-MATCH)

A clinical trial that will analyse patients’ tumours to determine whether they contain genetic abnormalities for which a targeted drug exists (that is, “actionable mutations”) and assign treatment based on the abnormality.